| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
229,860,000 |
| Market
Cap: |
485.00(M) |
| Last
Volume: |
562,074 |
Avg
Vol: |
229,763 |
| 52
Week Range: |
$1.45 - $5.46 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.1 |
| Insider 6 Months : 4.1 |
| Insider 3/6 Months : 8.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Palatin Technologies is a biopharmaceutical company developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Co.'s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Co.'s primary product, Vyleesi®, is a melanocortin receptor agonist, is an as needed therapy used in anticipation of sexual activity and self-administered in the thigh or abdomen via a single-use subcutaneous auto-injector by premenopausal women with hypoactive sexual desire disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
6,000 |
6,000 |
6,000 |
26,000 |
| Total Buy Value |
$12,703 |
$12,703 |
$12,703 |
$57,245 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
1 |
1 |
1 |
3 |
| Total Shares Sold |
11,700 |
16,898 |
16,898 |
16,898 |
| Total Sell Value |
$23,434 |
$36,493 |
$36,493 |
$36,493 |
| Total People Sold |
1 |
3 |
3 |
3 |
| Total Sell Transactions |
1 |
3 |
3 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wills Stephen T |
Exec VP - Operations & CFO |
• – – |
2010-03-26 |
4 |
D |
$0.26 |
$24,729 |
D/D |
(95,113) |
409,762 |
|
- |
|
| Wills Stephen T |
Exec VP - Operations & CFO |
• – – |
2010-03-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
300,000 |
504,875 |
|
- |
|
| Spana Carl |
President & CEO |
• • – |
2010-03-26 |
4 |
D |
$0.26 |
$32,086 |
D/D |
(123,407) |
463,466 |
|
- |
|
| Spana Carl |
President & CEO |
• • – |
2010-03-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
375,000 |
586,873 |
|
- |
|
| Wills Stephen T |
Exec VP - Operations & CFO |
• – – |
2009-12-31 |
4 |
D |
$0.37 |
$27,241 |
D/D |
(73,625) |
204,875 |
|
- |
|
| Wills Stephen T |
Exec VP - Operations & CFO |
• – – |
2009-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
250,000 |
278,500 |
|
- |
|
| Hallam Trevor |
Exec VP - Research & Dev |
• – – |
2009-12-31 |
4 |
D |
$0.37 |
$27,241 |
D/D |
(73,625) |
178,875 |
|
- |
|
| Hallam Trevor |
Exec VP - Research & Dev |
• – – |
2009-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
250,000 |
252,500 |
|
- |
|
| Spana Carl |
President & CEO |
• • – |
2009-12-31 |
4 |
D |
$0.37 |
$29,896 |
D/D |
(80,800) |
211,873 |
|
- |
|
| Spana Carl |
President & CEO |
• • – |
2009-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
250,000 |
292,673 |
|
- |
|
| Proquest Associates Ii Llc |
officerTitle |
– – • |
2005-11-29 |
4/A |
S |
$3.90 |
$1,402,318 |
D/D |
(358,000) |
5,803,972 |
|
- |
|
| Schreiber Alain |
officerTitle |
– – • |
2005-11-29 |
4 |
S |
$3.90 |
$1,402,318 |
D/D |
(358,000) |
5,803,972 |
|
- |
|
| Hallam Trevor |
Exec. VP - R&D |
• – – |
2005-11-10 |
4 |
B |
$2.01 |
$5,059 |
D/D |
2,500 |
2,500 |
2.74 |
- |
|
| Wills Stephen T |
Exec. VP & CFO |
• – – |
2005-11-10 |
4 |
B |
$2.01 |
$8,040 |
D/D |
4,000 |
28,500 |
2.74 |
- |
|
| Spana Carl |
President & CEO |
• • – |
2005-11-10 |
4 |
B |
$2.03 |
$10,150 |
D/D |
5,000 |
42,673 |
2.81 |
- |
|
| King Pharmaceuticals Inc |
10% Owner |
– – • |
2005-09-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,675,461 |
|
- |
|
| Wills Stephen T |
Exec. VP and CFO |
• – – |
2005-05-25 |
4 |
B |
$1.94 |
$7,935 |
D/D |
4,000 |
24,500 |
2.74 |
- |
|
| Prendergast John K A |
Director |
– • – |
2005-05-25 |
4 |
B |
$2.06 |
$8,314 |
D/D |
4,000 |
17,673 |
2.39 |
- |
|
| Spana Carl |
President and CEO |
• • – |
2005-05-25 |
4 |
B |
$2.05 |
$10,364 |
D/D |
5,000 |
37,673 |
2.81 |
- |
|
| Wills Stephen T |
Exec. Vice President and CFO |
• – – |
2004-11-11 |
4 |
B |
$2.56 |
$12,905 |
D/D |
5,000 |
20,500 |
2.74 |
- |
|
| Spana Carl |
President and CEO |
• • – |
2004-11-11 |
4 |
B |
$2.59 |
$15,593 |
D/D |
6,000 |
32,673 |
2.81 |
- |
|
| Wills Stephen T |
Executive VP and CFO |
• – – |
2003-11-18 |
4 |
B |
$2.74 |
$20,550 |
D/D |
7,500 |
15,500 |
2.74 |
- |
|
| Spana Carl |
President and CEO |
• • – |
2003-11-18 |
4 |
B |
$2.75 |
$27,500 |
D/D |
10,000 |
26,673 |
2.81 |
- |
|
248 Records found
|
|
Page 10 of 10 |
|
|
0.06 (2.93%) 
